General Population vs. Patient Preferences in Anticoagulant Therapy: A Discrete Choice Experiment

The Patient
Mehdi NajafzadehJoshua J Gagne

Abstract

Preference weights derived from general population samples are often used for therapeutic decision making. In contrast, patients with cardiovascular disease may have different preferences concerning the benefits and risks of anticoagulant therapy. Using a discrete choice experiment, we compared preferences for anticoagulant treatment outcomes between the general population and patients with cardiovascular disease. A sample of the general US population and a sample of patients with cardiovascular disease were selected from online panels. We used a discrete choice experiment questionnaire to elicit preferences in both populations concerning treatment benefits and risks. Seven attributes described hypothetical treatments: non-fatal stroke, non-fatal myocardial infarction, cardiovascular death, minor bleeding, major bleeding, fatal bleeding, and the need for monitoring. We measured preference weights and maximum acceptable risks in both populations. A total of 352 individuals from the general population and 341 patients completed the questionnaire. After propensity score matching, 284 from each group were included in the analysis. On average, the general population members valued a 1% increased risk of fatal bleeding as being the s...Continue Reading

References

Nov 29, 1990·The New England Journal of Medicine·UNKNOWN Boston Area Anticoagulation Trial for Atrial Fibrillation InvestigatorsJ Philip Kistler
Feb 9, 1986·Journal of Health Economics·G W Torrance
Sep 2, 1999·Health Economics·F Andersson, C H Lyttkens
Jan 13, 2006·BMJ : British Medical Journal·Niteesh K ChoudhryStephen B Soumerai
Jul 16, 2008·PharmacoEconomics·Emily Lancsar, Jordan Louviere
Oct 2, 2008·Risk Analysis : an Official Publication of the Society for Risk Analysis·F Reed JohnsonBruce E Sands
Sep 1, 2009·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN RE-LY Steering Committee and Investigators
Dec 1, 2009·Health Economics·Stirling Bryan, Sue Jowett
Feb 12, 2011·Medical Decision Making : an International Journal of the Society for Medical Decision Making·George Van HoutvenA Brett Hauber
Aug 13, 2011·The New England Journal of Medicine·Manesh R PatelUNKNOWN ROCKET AF Investigators
Aug 30, 2011·The New England Journal of Medicine·Christopher B GrangerUNKNOWN ARISTOTLE Committees and Investigators
Jul 13, 2012·Circulation. Cardiovascular Quality and Outcomes·Sebastian SchneeweissJerry Avorn
Jul 17, 2012·The Annals of Thoracic Surgery·Betty C TongPeter K Smith
Jan 23, 2013·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·F Reed JohnsonJohn F P Bridges
Feb 15, 2013·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Guangxiang ZhangDavid L Brown
Nov 13, 2014·Circulation. Cardiovascular Quality and Outcomes·Mehdi NajafzadehSebastian S Schneeweiss
Nov 13, 2015·Expert Review of Pharmacoeconomics & Outcomes Research·David John Mott, Mehdi Najafzadeh
Dec 16, 2017·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Tommi TervonenKevin Marsh

❮ Previous
Next ❯

Citations

Aug 24, 2020·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·David J MottTommi Tervonen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.